Targeting the TR4 nuclear receptor-mediated IncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression

Hangchuan Shi1,2 · Yin Sun2 · Miao He2 · Xiong Yang1,2 · Michiaki Hamada3,5 · Tsukasa Fukunaga3 · Xiaoping Zhang1 · Chawnshang Chang2,4

Received: 7 August 2018 / Accepted: 13 May 2019 / Published online: 9 September 2019 © The Author(s) 2019. This article is published with open access

Abstract
Renal cell carcinoma (RCC) is one of the most lethal urological tumors. Using sunitinib to improve the survival has become the first-line therapy for metastatic RCC patients. However, the occurrence of sunitinib resistance in the clinical application has curtailed its efficacy. Here we found TR4 nuclear receptor might alter the sunitinib resistance to RCC via altering the TR4/IncTASR/AXL signaling. Mechanism dissection revealed that TR4 could modulate IncTASR (ENST00000600671.1) expression via transcriptional regulation, which might then increase AXL protein expression via enhancing the stability of AXL mRNA to increase the sunitinib resistance in RCC. Human clinical surveys also linked the expression of TR4, IncTASR, and AXL to the RCC survival, and results from multiple RCC cell lines revealed that targeting this newly identified TR4-mediated signaling with small molecules, including tretinoin, metformin, or TR4-shRNAs, all led to increase the sunitinib sensitivity to better suppress the RCC progression, and our preclinical study using the in vivo mouse model further proved tretinoin had a better synergistic effect to increase sunitinib sensitivity to suppress RCC progression. Future successful clinical trials may help in the development of a novel therapy to better suppress the RCC progression.

Introduction
Renal cell carcinoma (RCC) is one of the most lethal urological tumors with a worldwide mortality of about 90,000 annually based on the WHO statistics [1]. Although there is a higher incidence of detection of small renal masses through improved diagnosis, close to one-third of patients will eventually develop metastatic lesions in the course of the disease [2]. Drugs targeting vascular endothelial growth factor (VEGF) or mammalian target of rapamycin pathway have shown robust clinical effects and changed paradigm of treatment of metastatic RCC [3]. In particular, sunitinib, being able to bring significant prolongation of progression-free survival in patients, has become the first-line medicine in the systematic therapy for metastatic RCC. However, inherent or acquired resistance to these approaches have been found in most patients [4]. Thus far there is no clear understanding of the molecular mechanism responsible for this therapy resistance [5, 6].

Hypoxia is a frequent occurrence in a solid tumor mass, which has functional consequences for tumor progression [7], and RCC is a hypoxia-driven malignancy [8]. As reported, about 60–80% of RCC patients have loss-of-function coding
mutations in the Von Hippel-Lindau (VHL) gene and histological necrosis, suggesting that hypoxia plays critical roles in the progression of RCC [9]. The main target of sunitinib is the vessels that nourish the tumor cells, thus sunitinib application will likely generate hypoxic conditions for the tumor cells. At the same time, sunitinib will also inhibit receptor tyrosine kinases in the RCC cells, and overall resistance to sunitinib likely will derive from the combined effects on vessels and on tumor cells. For practical reasons, we will examine the molecular mechanisms of sunitinib resistance in RCC cells with a focus on the role of Testicular orphan receptor 4 (TR4) under hypoxic conditions compared with normoxic conditions.

TR4 (nuclear receptor subfamily 2, group C, member 2) is a member of the nuclear receptor superfamily and encodes a 67-kDa protein [10]. Like other nuclear receptors, TR4 is a ligand-activated transcription factor. The activated receptor/ligand complex is translocated to the nucleus where it binds to hormone response elements of target genes [11]. Early studies showed that the protein encoded by TR4 functions in many biological processes in prostate cancer [12]. But its role in RCC is still not well understood.

AXL belongs to the Tyro3-Axl-Mer (TAM) family of receptor tyrosine kinases with growth arrest-specific 6 (GAS6) protein as the common ligand. GAS6/AXL stimulates multiple pro-tumorigenic signalings associated with tumor progression such as cellular adhesion, invasion, migration, proliferation, and anti-apoptosis. Recently, AXL signaling was found essential for VEGF-mediated activation of PI3K/AKT and migration of endothelial cells, suggesting that overexpression of AXL may serve as a mechanism of resistance to anti-angiogenic therapies [13].

Long noncoding RNAs (lncRNAs) over 200 bp in length have been found to be important for numerous molecular processes [14]. An increasing number of lncRNAs have been reported to be involved in RCC progression [15]. However, the proven roles of lncRNAs involved in RCC resistance to sunitinib are limited [16].

Tretinoin, a derivative of Vitamin A, can function via targeting the retinoic acid receptor alpha (RARα)-mediated signals to alter the cell apoptosis [17], and has been used as a medication to treat acute promyelocytic leukemia (APL) for decades [18]. However, its linkage to altering the TR4-mediated signals remains unclear.

Here we demonstrate that hypoxia increases TR4, which plays a critical role in regulating RCC resistance to sunitinib through lnCTASR (ENST00000600671.1) that in turn regulates AXL. Thus, we delineated a novel pathway for TR4’s effects on the sunitinib resistance as well as provide a mechanistic explanation, and more importantly, we provided potential therapeutic approaches to overcome this resistance.

**Results**

**Hypoxia treatment can increase RCC resistance to sunitinib via upregulating TR4 expression**

As early studies indicated that hypoxia might impact the progression of several solid tumors including RCC [7, 19, 20], we were interested to see if hypoxia may also influence the RCC proliferation under sunitinib treatment. As shown in Fig. 1a, b, we found hypoxia treatment could increase RCC sunitinib resistance in RCC OSRC-2 and SW839 cells at 5 and 10 μM. We also calculated the IC50 of sunitinib in OSRC-2 cells at 6.5 μM.

As recent studies indicated that TR4 could also impact RCC progression [21, 22], we were interested to see if hypoxia may function via altering TR4 to influence the sunitinib sensitivity. The results revealed that hypoxia could significantly increase TR4 expression in both RCC OSRC-2 and SW839 cells (Fig. 1c). Importantly, interruption approaches with MTT assay also revealed that increasing TR4 expression could promote RCC sunitinib resistance (Fig. 1d, e), while suppressing TR4 via adding TR4-shRNA resulted in a decrease in the sunitinib resistance in OSRC-2 and SW839 cells (Fig. 1f, g). Furthermore, we evaluated TR4’s role in the RCC sunitinib resistance after hypoxia treatment. The results revealed that after the treatment of hypoxia, only knocking down TR4 led to increase sunitinib sensitivity of OSRC-2 and SW839 cell lines, but additional TR4 likely failed to exert an impact beyond the hypoxia-induced TR4 (Supplementary Fig. 1).

Taken together, results from Fig. 1a–g suggest that hypoxia may increase the RCC sunitinib resistance in RCC cells through regulating TR4 expression.

**Mechanism dissection of how TR4 can influence RCC sunitinib resistance: via altering AXL expression**

To dissect the molecular mechanism of how hypoxia-induced TR4 can alter the RCC sunitinib resistance, we examined several genes that have been reported to play important roles on altering sunitinib sensitivity [4, 6, 16]. We then focused on the AXL, a key player in regulating the sunitinib resistance [13, 16], and results revealed that increasing the TR4 expression with TR4-cDNA or suppressing TR4 with TR4-shRNA altered the AXL mRNA expression in both RCC OSRC-2 and SW839 cells (Fig. 2a, b). Western blot analysis also confirmed alteration of TR4 protein expression changed the expression of AXL in both OSRC-2 and SW839 cells (Fig. 2c, d).

To further dissect the molecular mechanism of how TR4 can alter the AXL expression, we then applied the bioinformatics analysis to characterize the potential
promoter structure of AXL (Fig. 2e, f) and tested TR4’s binding to the potential TR4 response elements (TR4REs). However, results from the Chromatin immunoprecipitation (ChIP) in vivo binding assay with anti-TR4 antibody revealed that TR4 failed to bind to those potential TR4REs located on the AXL 5’ promoter region in OSRC-2 cells, or OSRC-2 cells with overexpressed TR4, or OSRC-2 cells after hypoxia treatment (Fig. 2g).

Taken together, the results from Fig. 2a–g suggest that while TR4 may influence RCC sunitinib resistance via altering AXL expression, TR4 may not do so via direct transcriptional regulation.

**TR4 may modulate the AXL expression via altering the IncTASR expression**

We then examined if TR4 may alter the AXL expression via IncRNAs that could impact the progression of many tumors [16, 23]. We applied a bioinformatic RNA profiling array analysis to uncover the potential RNA–RNA interactions and identified eight IncRNAs candidates that might be able to interact with AXL and concurrently are highly related to sunitinib resistance in RCC (Fig. 3a).

Among these eight potential IncRNAs, we found the expression of IncRNA AC010300.1-201 (ENST00000600671.1,
labeled as lncRNA7) and lncRNA MUC2-201 (ENST00000361558.7, labeled as lncRNA1) changed significantly after alterations of TR4 (Fig. 3b, c). As it is technically challenging to study lncRNA1, which is 12,667 kb in length, we decided to first focus on lncRNA7 for further characterization. In addition, results from the RIP assay also revealed that lncRNA EMX2OS-204 (ENST00000440007.5, labeled as lncRNA2) and lncRNA EMX2OS-206 (ENST00000551288.5, labeled as lncRNA5) could interact with TR4 (Fig. 3d). These two lncRNAs are different splice variants of the transcript of EMX2OS and highly overlapped, so they were combined and labeled as lncRNA2/5.

**Fig. 2** TR4 can influence renal cell carcinoma sensitivity to sunitinib via altering AXL expression. Under TR4 overexpressed and knocked down conditions, the expression of AXL changes along with TR4 at mRNA level in OSRC-2 (a) and SW839 (b) cells. Similar results are shown in protein level by Western blot (left) with quantifications (right) in OSRC-2 (c) and SW839 (d) cells. e TR4 binding profile map predicted by JASPAR. f Speculated potential promoter structure of AXL binding to the TR4 response element (TR4RE). g ChIP assay shows the binding capacity of TR4REs to the speculated promoter structure of AXL under the condition of normoxia, hypoxia and TR4 overexpression in OSRC-2 cells. In a and b, data is presented as mean ± s.e.m., *p < 0.05, **p < 0.01.
We then knocked down lncRNA7 and lncRNA2/5 in OSRC-2 cells and results revealed that suppressing these lncRNAs decreased the AXL mRNA expression (Fig. 3e), with increased RCC sensitivity to sunitinib by 55% at 10 μM (lncRNA7) and 38% at 10 μM (lncRNA2/5) (Fig. 3f, g). We decided to choose lncRNA7 (renamed as lncTASR [lncRNA 534 H. Shi et al.])
Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the...

![Image](https://via.placeholder.com/150)

**Fig. 3** TR4 may alter AXL expression via altering lncTASR. a Bioinformatics analysis of potential lncRNAs that are both associated with RCC sunitinib resistance and have predicted binding sites to the mRNA of AXL. After TR4 was overexpressed (b) and knocked down in OSRC-2 cells (c), the expression of candidate lncRNA AC010300.1-201 (ENST00000600671.1, labeled as lncRNA7) changes along with TR4 at RNA level. d RIP assay identifies candidate lncRNAs EMX2OS-204 (ENST00000440007.5, labeled as lncRNA2) and EMX2OS-206 (ENST00000551288.5, labeled as lncRNA5), which can interact with TR4. These two lncRNAs are different splice variants of the transcript of EMX2OS and highly overlapped, so they are combined and labeled as lncRNA2/5. e AXL expression decreases at the mRNA level after knocking down lncRNA7 and lncRNA2/5. The sensitivity to Sunitinib can be increased by knocking down lncRNA7 (f) and lncRNA2/5 (g) in OSRC-2 cells. We named lncRNA7 lncTASR (lncRNA of TR4/AXL signaling related to sunitinib resistance) and h shows the predicted functional (1 kb) domain (2) of lncTASR, its full length (1) (5 kb) form and the constructed mutant (3) form of functional domain. i The sunitinib resistance can be increased only by introducing overexpressed full length lncTASR in OSRC-2 cells. j Western blot (left) with quantification (right) shows the expression of AXL when introducing different combinations of different lncTASR constructs. k The change of AXL expression caused by TR4 can be reversed by altering lncTASR. l, m The alteration of the RCC sensitivity to sunitinib influenced by TR4 can be reversed by lncTASR. In all but a and h, data is presented as mean ± s.e.m., *p < 0.05, **p < 0.01

of TR4(AXL signaling related to Sunitinib Resistance) for further study, since its effect on changing the sunitinib resistance is more significant than that of lncRNA2/5.

The full length of lncTASR is 5 kb with a predicted binding motif of AXL located in the 5′ end of the lncRNA (Fig. 3h). It appears that only the full length lncTASR, not a one kilobase region containing the binding motif, is capable of regulating sunitinib sensitivity, suggesting that the binding alone is not sufficient to regulate AXL (Fig. 3i). We further demonstrated this finding at the protein level showing that the full length lncTASR, and not the 1 kb region (functional domain) of lncTASR can influence the expression of AXL (Fig. 3j).

To further characterize the functional structure of lncTASR, we designed a mutant functional domain of lncTASR (Fig. 3h), and then tested the expression of AXL by introducing different combinations of our three lncTASR constructs (full length, functional domain, and mutant functional domain). Interestingly, we found that if we introduced both functional domain and full length lncTASR, then the functional domain could compete with the full length lncTASR and interfere with the expression of AXL (Fig. 3j). These results suggest that 1 kb region containing the binding motif of lncTASR is necessary but not sufficient for regulating AXL expression by lncTASR.

Furthermore, we demonstrated that TR4 might modulate the AXL expression via altering the lncTASR. Figure 3k showed that lncTASR could reverse the TR4 impact on the AXL expression. Importantly, interruption via adding lncTASR or knocking down lncTASR could also reverse TR4’s impact on the regulation of RCC sensitivity to sunitinib (Fig. 3l, m). It appears that the lncTASR’s regulation of sunitinib sensitivity and AXL expression are not completely linear in that its impact on sunitinib sensitivity is more significant than on AXL expression (Fig. 3i and k). It is possible that lncTASR may regulate targets other than AXL, but the exact molecular details remain to be examined.

Together, results from Fig. 3a–m suggest that TR4 may function via lncTASR to alter AXL expression.

**Mechanism dissection of how TR4 can modulate lncTASR expression: via transcriptional regulation**

To further dissect the mechanism of how TR4 can modulate lncTASR expression, we examined whether TR4 could regulate lncTASR at the transcriptional level and identified three potential TR4REs on the 5′ promoter region of lncTASR (Fig. 4a). Results from ChIP assay with anti-TR4 antibody revealed that TR4 could bind to the TR4RE III on the 5′ promoter region of lncTASR in OSRC-2 cells (Fig. 4b).

We also constructed the lncTASR promoter luciferase reporter by inserting a 1.5 kb 5′ promoter region of lncTASR containing TR4RE III into the pGL3 luciferase backbone as well as a construct with the mutated TR4RE III (Fig. 4c). As expected, the luciferase assay results revealed that adding TR4 significantly increased luciferase activity in OSRC-2 cells transfected with wild type lncTASR promoter, but not in the cells with the mutant lncTASR promoter (Fig. 4d).

Together, results from Fig. 4a–d suggest that TR4 can modulate the lncTASR expression via transcriptional regulation.

**Mechanism dissection of how TR4-lncTASR axis can alter AXL expression: via binding to its 5′ UTR region**

Next, to dissect the mechanism how TR4-lncTASR can modulate AXL expression, we applied the RNA pull-down assay and results revealed that lncTASR could bind directly to the 5′ UTR of the AXL mRNA (Fig. 4e). Results from mRNA stability assay also revealed that altering TR4-lncTASR led to the change of AXL mRNA stability (Fig. 4f).

Together, results from Fig. 4a–f suggest that TR4 could modulate the lncTASR expression via transcriptional regulation, which might then alter the AXL protein expression via enhancing the stability of AXL mRNA to increase the RCC sunitinib resistance.

**Human clinical data support the TR4/lncTASR/AXL axis in the RCC progression**

Human clinical data from TCGA and OncoLnc databases suggest that the RCC patients with higher expression of
TR4, lncTASR, or AXL all have significantly shorter overall survival (Fig. 5a–c), and a positive correlation between expression of TR4 and AXL was also found from TCGA database \( \text{n} = 522 \) (Fig. 5d).

Together, results from human clinical sample surveys suggest that TR4/lncTASR/AXL signaling is critical for the survival of RCC patients.

**Targeting TR4/lncTASR/AXL signaling with small molecules including TR4-shRNA, tretinoin, or metformin all led to increase sunitinib sensitivity to better suppress the RCC progression**

To link the above findings to the future potential clinical application, we were interested to find if any small molecules can be used as possible therapeutic interventions to target this newly identified TR4/lncTASR/AXL signaling. Among several likely candidates, including TR4-siRNAs [25, 26], miRNAs [22], TR4 potential antagonists/agonists including tretinoin (Hu et al. unpublished data), and metformin [27] that can suppress the TR4 function, we found that adding TR4-shRNA (See Fig. 1f, g), metformin or tretinoin (up to 10 μM), could also result in increasing the sunitinib sensitivity to better suppress the RCC OSRC-2 cell growth (Fig. 6a, b, Supplementary Fig. 2a, b). Consistent with the biological effect of tretinoin and metformin, expression of tretinoin responsive genes CRABP2 and \( \text{RAR} \alpha \) was increased by tretinoin while expression of \( \text{SREBP1c} \) increased in response to metformin (Supplementary Fig. 3).

Mechanism studies indicated that tretinoin (Fig. 6c) or metformin (Supplementary Fig. 2c) indeed have synergetic effects with sunitinib to better suppress the RCC viability. As expected, adding tretinoin (Fig. 6d) or metformin (Supplementary Fig. 2d) also led to suppress the expression of both TR4 and AXL in OSRC-2 cells. Interestingly, when
we compared the impacts of these two small molecules on altering sunitinib sensitivity, we found that metformin could have synergetic effect with the high-dose of sunitinib (7.5–15 μM), yet tretinoin could have synergetic effect with low-dose of sunitinib (1.0–7.5 μM) in the OSRC-2 cells.

To further address whether the anti-sunitinib resistance function of tretinoin is through TR4 or other targets, we designed an assay to test the changes of sunitinib-sensitivity after TR4-knockdown in OSRC-2 cells with/without tretinoin, compared with OSRC-2 cells without TR4-knockdown. The results showed that Tretinoin has less synergetic effects with the low-dose of sunitinib (1.0–7.5 μM) on TR4-knockdown OSRC-2 cells (with less difference change compared with OSRC-2 without TR4-knockdown) (Fig. 6f, g). To confirm that tretinoin can regulate AXL expression and RCC sunitinib resistance mainly through TR4, we checked TR4 and AXL expressions in OSRC-2 cells with/without TR4-shRNA and with/without tretinoin. Our results in Fig. 6h showed that tretinoin decreases both TR4 and AXL protein expressions in OSRC-2 cells with pLKO control cells, but does not decrease TR4 and AXL expressions in TR4-knockdown OSRC-2 cells.

We also tested whether metformin plays a role in anti-Sunitinib resistance through TR4. We found that although metformin has less synergetic effects with the high-dose of sunitinib on TR4-knockdown OSRC-2 cells, metformin continues to decrease TR4 and AXL expressions in TR4-knockdown OSRC-2 cells (Supplementary Fig. 2f–h).

These results suggest that tretinoin can lead to increase sunitinib sensitivity through TR4 and AXL signaling, but we cannot conclude the anti-sunitinib resistance function of metformin is mainly through TR4. We therefore decided to choose tretinoin to test its in vivo roles to increase the sunitinib sensitivity.

Preclinical study using in vivo mouse model to demonstrate targeting the TR4/lncTASR/AXL signaling using tretinoin can increase the RCC sensitivity to sunitinib

To confirm all above in vitro cell lines data in the in vivo nude mouse model, we performed the orthotopic left kidney capsule implantation using OSRC-2 cells labeled with firefly luciferase. After 14 days’ tumor development, we treated four groups of mice with vehicle control (DMSO), sunitinib (20 mg/kg), tretinoin (25 mg/kg) or both sunitinib and Tretinoin by intraperitoneal injection once every other day. The IVIS was used to monitor tumor growth every 7 days. After 28 days of drug treatment, we sacrificed the mice and examined the tumor formation and metastasis, and tumor weights from the abdominal and thoracic cavities.
Fig. 6 Targeting TR4/IncTASR/AXL signaling with tretinoin can increase sunitinib sensitivity to better suppress the RCC progression. a Tretinoin alone was not toxic to RCC cells. b Tretinoin can enhance the sensitivity of RCC to sunitinib when combined with low dose sunitinib. c Tretinoin actually has synergetic effects when combined with sunitinib in the treatment of RCC cells. d Western blotting (left) with quantification (right) shows that the expression of both TR4 and AXL decreased after treated with tretinoin. e Tretinoin can reverse the resistance of RCC cells to sunitinib caused by overexpressed TR4. f Viability of OSRC-2 cells in sunitinib with/without tretinoin and with/without TR4-shRNA. g DID (difference in difference) analysis shows that TR4-knockdown OSRC-2 cells have less difference change in sunitinib resistance with/without tretinoin compared with OSRC-2 cells without TR4-knockdown. h Tretinoin decreases both TR4 and AXL protein expressions in OSRC-2 cells with pLKO vehicle, but does not decrease TR4 and AXL expressions in TR4-knockdown OSRC-2 cells. Data is presented as Mean ± s.e.m., **p < 0.01, ***p < 0.001, ns not significant.
The IVIS mice images showed that the tretinoin + sunitinib group had a lower tumor luminescence value than the other three groups (Fig. 7a). After mice were sacrificed, the tumor image (Fig. 7b, the kidney with orthotopically planted tumor is on the right and the contralateral kidney from the same mouse is on the left) and tumor weight.
Fig. 7 The TR4/IncTASR/AXL signaling in RCC resistance to sunitinib in xenograft mouse model. a IVIS imaging was used to determine the tumor luminescence value of representative mice over time. b Representative images of tumors from different groups. c After 28 days treatments (DMSO, sunitinib 20 mg/kg/q.d., or tretinoin 25 mg/kg/q.d., or both), the mice were sacrificed and the tumor weights were measured by the weight of the left kidney with tumor minus the weight of right normal kidney from the same mouse. d Representative photos and bioluminescent images of metastases in abdominal cavity and thoracic cavity. e Total metastatic foci of each mouse in four groups (f) and quantification for the mice metastasis ratio of each group. g Three tumor samples were randomly picked up from each group, the tissues were lysed and then the TR4, staining (upper) with quantification (lower) to identify the level of TR4 in four groups. For c, and e–h, data is presented as mean ± s.e.m., *p < 0.05, **p < 0.01 compared with the controls.

The TR4/lncTASR/AXL signaling in RCC resistance to sunitinib, raising the possibility of using small molecule inhibitors to target to increase the sunitinib efficacy and overall survival (26.4 versus 21.8 months, p = 0.049) compared to interferon alpha (IFN-α) therapy [31]. However, RCC progression usually recurs after a median of 6–15 months of sunitinib therapy, suggesting the existence of intrinsic as well as acquired drug resistance [4].

Due to the difficulty in obtaining clinical samples from metastatic RCC patients, conventional in vitro studies on the resistance mechanisms were based on the establishment of sunitinib-resistant cell lines by chronic exposure of this drug. However, considering the pharmacologic mechanism of sunitinib, which mainly targets the VEGFR of the endothelial cells constructing the vessels around RCC solid tumors, the in vitro induced sunitinib resistance in RCC cells has weak clinical relevance. To approximate in vitro tissue culture cells to in vivo condition after sunitinib treatment, which results in a hypoxic tumor microenvironment, we attempted a comparison of the molecular changes of RCC cells under hypoxia versus normoxia conditions with a focus on TR4 protein. This is an extension of the recent study of another nuclear hormone receptor, androgen receptor, in its association with the acquired sunitinib resistance [32]. These studies indicate that nuclear hormone receptors can play a significant role in RCC resistance to sunitinib, raising the possibility of using small molecule hormones as adjuvant therapies for sunitinib.

Generally, the resistance mechanisms to tyrosine kinase inhibitors (TKIs) can be divided into several distinct groups including those affected by the tumor microenvironment, increased tumor invasiveness and metastasis, activation of alternative signaling pathways are the major focus and AXL, along with c-MET, were identified as important mechanisms of resistance of multiple tumors to TKIs [35, 36], such as non-small cell lung cancer to Gefitinib or Erlotinib [37], gastrointestinal stromal tumors to Imatinib [38], and HER2-positive breast cancer to Lapatinib [39]. Most recently, Qu et al. found that combined with BMS-777607, a small-molecule inhibitor of both c-MET and AXL, RCC cells could overcome the sunitinib resistance [16]. Moreover, Zhou et al. showed that Cabozantinib, a FDA proven TKI with multiple targets including c-MET and AXL [40], could rescue RCC sunitinib resistance both in vitro and in vivo [13]. In a Phase II study compared with sunitinib, cabozantinib has been tested on metastatic RCC patients (NCT01835158) [41]. However, as a promising target to increase the sunitinib efficiency, there is limited understanding of how AXL is regulated, as well as its exact role in the resistance to TKI.

Our study identified a signaling axis, TR4/IncTASR/AXL, which is associated with the RCC sunitinib
resistance. This is the first linkage of the regulation of AXL with TR4, a nuclear transcription factor, and may provide several potential targets to influence the RCC sunitinib resistance. In addition to the TR4-shRNAs or some selective miRNAs [22, 25, 26], we were more interested in using small molecules to target the TR4 function. As the structure of the TR4 ligand binding domain indicates that it might be activated by retinoic acids as that in RXRα [42], we find variants of retinol, including tretinoin, can regulate TR4 function. In addition, metformin, a currently used medicine to treat diabetes [43], was also found to be able to suppress the TR4 expression [27]. Indeed, our results revealed that both tretinoin and metformin could suppress the expression of TR4 and AXL, and increase the sunitinib sensitivity to better suppress the RCC cell growth (Fig. 6).

Early studies indicated that metformin at 5–50 mM could effectively suppress in vitro tumor growth in cells from lung cancer, prostate cancer, and kidney cancer [44–46]. Also, in vivo mice studies indicated that metformin at 250 mg/kg body weight (or 40 μM in plasma) could effectively suppress the colon cancer growth [47], yet none of the 23 currently ongoing human clinical trials has yielded any positive outcome in overall survival [48–50] with metformin.

In contrast, tretinoin, an analog of vitamin A, was first proven as a medication for acne [51], and has been used to treat APL since the 1990s [52]. Recent studies also reported its potential role on suppressing other cancers such as lung cancer [53] and thyroid cancer [54]. In this regard, our in vitro cell line results also revealed that tretinoin had synergistic effects with lower concentrations of sunitinib (Fig. 6a, b), a more achievable concentration than that for metformin to have synergistic effects with sunitinib (Fig. 6c, d).

Notably, we found that the nude mice treated with tretinoin became weaker than the ones without tretinoin.
The weak mice had low body weight and thin muscles (Supplementary Fig. 4). The similar tretinoin in vivo adverse effect was also reported when combined with arsenic trioxide [55]. However, the weight loss did not seem to influence the tumor size. Mice from the tretinoin group grew similar size tumors than mice from the DMSO group, and mice from the tretinoin + sunitinib group grew the smallest tumor. It is possible that the modulatory effect of tretinoin on cytokines and lymphocytes may contribute to the overall weakness of the mice especially considering that nude mice are immunologically impaired [56, 57]. Future studies involving clinical use of tretinoin in RCC will benefit from close monitoring of the immune status of patients.

In conclusion, our study identified a TR4/lncTASR/AXL signaling pathway, which is associated with the RCC sunitinib resistance. Preclinical studies demonstrated that tretinoin can be a novel promising drug to overcome this RCC resistance by decreasing TR4 and AXL, establishing the foundation for further testing this combination in a clinical setting to enhance sunitinib efficacy in RCC patients.

**Methods**

**Cell culture**

Human RCC cell lines OSRC-2 and SW839 were obtained from the American Type Culture collection (ATCC, Rockville, MD). Cells were cultured in DMEM media containing 1% penicillin and streptomycin, supplemented with 10% fetal bovine serum, in a 5% (v/v) CO2 humidified incubator at 37 °C.

**Hypoxia**

Hypoxia (0.5% O2, 5% CO2, 94.5% N2) was achieved using an In Vivo2 hypoxic workstation (Ruskin Technologies, Sanford, ME) or in a positive pressure chamber receiving gas from a custom-mixed tank (Airgas, Rochester, NY).

**MTT assay**

Cell proliferation rates were measured using MTT. After being transfected with plasmids for 24 h, SW839 or OSRC-2 cells were seeded at 1000 per well in 96-well plate. The assay was performed after 24 h treatment of gradient concentrations of sunitinib with/without tretinoin. 0 μM means the same volume of DMSO as other concentration of sunitinib. MTT reagent was added to each well and then the plate was incubated for 2 h at 37 °C. Before the endpoint of incubation, we added DMSO to dissolve the ppt and the absorbance was measured at 570 nm. Each sample was assayed in triplicate and multiple times.

**RCC cell lines with differential stable expressions of TR4**

The pWPI-TR4/pWPI-vec, or pLKO-shTR4#1/pLKO-shTR4#2/pLKO1-vec, the psPAX2 packaging plasmid, and the pMD2.G envelope plasmid were transfected into 293T cells using the standard calcium phosphate transfection method. After 48 h, the lentivirus supernatant was collected for immediate use or frozen at −80 °C for later use. OSRC-2 and SW839 cells were infected with the lentiviral vectors to generate overexpressed TR4 and TR4-knockdown stable cell populations.

**Quantitative real-time PCR (qRT-PCR)**

RNAs were extracted using Trizol reagent (Invitrogen, Grand Island, NY) and 1 μg of total RNA was subjected to reverse transcription using Superscript III transcriptase (Invitrogen). The qRT-PCR was then conducted using SYBR green by Bio-Rad CFX96 system. The expression of GAPDH mRNA level was used to normalize the expression level of a gene of interest using the 2−ΔΔCt method. The primers for GAPDH were: Forward: 5′-GGA GCG AGA TCC CTC CAA AAT-3′; and Reverse: 5′-GGC TGT TGT CAT ACT TCT CAT GG-3′. The primers for TR4 were: Forward: 5′-TCC CCA CGC ATC CAG ATA ATC-3′; and Reverse: 5′-GAT GTG AAA ACA CTC AAT GGG C-3′.

**Western blot**

Cells were lysed in RIPA buffer. Twenty micrograms proteins were loaded and then separated on 10% SDS/PAGE gel. PVDF membranes (Millipore, Billerica, MA) were then used for western transfer. After being blocked in 5% milk, the membranes were incubated with appropriate dilutions of specific primary antibodies against GAPDH (Santa Cruz, #sc-166574, Paso Robles, CA), β-actin (Abcam, #ab8227, San Diego, CA), TR4 (Abcam, #ab109301), or AXL (Abcam, #ab32828). After being incubated with HRP conjugated secondary antibodies, the blots were visualized using the ECL system (Thermo Fisher Scientific, Rochester, NY).

**RNA–RNA interaction prediction**

Based on the established methods described in a previous paper [58], we computed the interaction lncRNA partners of the 5′ region of AXL mRNA. An ultrafast RNA–RNA interaction prediction system Riblast (https://github.com/fukunagatsu/Riblast) [59] was utilized on a lncRNA
Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the... 543

RNA Immunoprecipitation (RIP)

Cells were lysed in RIPA buffer supplemented with RNase and protease inhibitor cocktail. RNase-free DNase (New England Biolabs, Rochester, NY) (400 U) was then added to the lysate and incubated on ice for 30 min. To test protein–RNA interaction, 5 µg of TR4 antibody was added into 500 µl of the supernatant and the mixture was incubated at −4 °C overnight (normal rabbit IgG as control). To test RNA–RNA interaction, 500 µl of the supernatant was incubated with a final concentration of 1 µM biotinylated AXL RNA bait (5′-TGA CAC CGA AGG GTG CCC GTG AGT C-3′). Protein A/G beads (for protein–RNA interaction) were pre-blocked by 15 mg/ml BSA in PBS. Pierce™ Streptavidin Agarose (Thermo Fisher Scientific™, #20347) beads (for RNA–RNA interaction) were pre-blocked by 10 µM RNA from torula yeast Type VI (MilliporeSigma, #R6625, St. Louis, MO) in PBS. The pre-blocked beads were then added to the antibody/bait-lysate mixture and incubated for another 2 h at −4 °C. The RNA/antibody or RNA/RNA complex was washed four times before RNA extraction, which is the same as described in qRT-PCR section.

Luciferase reporter gene assays

The 1.5 kb human lncTASR (ENST00000600671.1) promoter was cloned into pGL3 basic vectors (Promega, Madison, WI). Site-directed mutagenesis of the TR4 binding site in the lncTASR 5′ promoter was achieved by mutating part of the site to EcoRI cutting site (-GAATTC-). The DNA (pGL3 with wild type or mutant lncTASR promoter) was transfected into OSRC-2 cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instruction. PRL-TK was also transfected as an internal control to normalize the transfection efficiency. After 36 h transfection, luciferase activity was measured by Dual-Luciferase Assay (Promega) according to the manufacturer’s instruction.

Mouse model of orthotopic tumor implantation and drug administration

Six weeks old nude mice were purchased from NCI and injected with 1 × 10^6 pWPI-OSRC-2-Luc cells (mixed with Matrigel, 1:1) under the left subrenal capsule. After 7 days tumor development, mice were randomized into four groups and treated every other day by intraperitoneal injection, the groups were (1) DMSO control (four mice), (2) tretinoin 25 mg/kg (six mice), (3) sunitinib 20 mg/kg (four mice), or (4) sunitinib 20 mg/kg + tretinoin 25 mg/kg (six mice). Tumor development and metastasis were monitored by Fluorescent Imager (IVIS Spectrum, Caliper Life Sciences, Hopkinton, MA) once a week. After 28 days’ treatments, the mice were sacrificed, and tumors and any metastases were removed for studies. Tumor weights were measured and calculated by the weight of the left kidney with tumor minus the weight of the right normal kidney from the same mouse. Sample size estimation was based on our previous similar animal model results [21]. If the mouse died before being sacrificed at a predetermined date, it was excluded. All the animal experiments were performed in accordance with the guidelines of the University of Rochester Medical Center Animal Care and Use Committee for animal experiments. The investigators were not blinded to group allocations during the experiment.

Immunohistochemical (IHC)

Tissues were fixed in 10% (v/v) formaldehyde in PBS, embedded in paraffin, cut into 5 µm sections and used for IHC staining with human TR4 antibody (Abcam, #ab109301).

Statistics

Data are presented as mean ± s.e.m. from at least three independent experiments. Two-sided tests were conducted by SPSS 17.0 (SPSS Inc., Chicago, IL). p < 0.05 was considered statistically significant.

Acknowledgements We thank Karen Wolf for help with manuscript preparation. This work was supported by NIH grant (CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002) to China Medical University, Taichung, Taiwan). Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics.

Author contributions HS and YS conceived and designed the work, performed experiments, analyzed the data; and wrote the manuscript. HS and MH established the animal model and measured the sizes of xenograft tumors and did the IHC staining. HS and XY established protocols for cell lines and clinical data analysis. MH and TF established the RNA–RNA interaction prediction system and analyzed data. XZ and CC supervised the project, analyzed the data, and wrote the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Baldewijns MM, van Vlodrop JJ, Schouten LJ, Soetekouw PM, de Bruinie AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 1785:2008;133:55.

2. Staepler M, Rohrmann K, Haseke N, Stief CG, Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets. 2005;6:835–46.

3. Coppen C, Kollmannsberger C, Le L, Porzolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108:1556–63.

4. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992–1000.

5. Busch J, Seidel C, Weikert S, Wolff I, Kempekensteffen C, Weinkauf L, et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11:295.

6. Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M, et al. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 1855;2015:1–16.

7. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–9.

8. Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, et al. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther. 2012;11:383–92.

9. Schwaarzik J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russu P, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69:646–57.

10. Ding X, Yang DR, Xia L, Chen B, Yu S, Niu Y, et al. Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/ MMP2/MMP9 signals. Mol Cancer. 2015;14:16.

11. Liu S, Lin SJ, Li G, Kim E, Chen YT, Yang DR, et al. Differential roles of PPARgamma vs TR4 in prostate cancer and metabolic diseases. Endocr-Relat Cancer. 2014;21:R279–300.

12. Yu S, Wang M, Ding X, Xia L, Chen B, Chen Y, et al. Testicular orphan nuclear receptor 4 is associated with the radio-sensitivity of prostate cancer. Prostate. 2015;75:1632–42.

13. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–97.

14. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, et al. LincRNA-p21 suppresses target mRNA translation. Mol cell. 2012;47:648–55.

15. Lorenzen JM, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol. 2016;12:360–73.

16. Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-transmitted IncARSAR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653–68.

17. Liu X, Chen J, Yu S, Yan L, Guo H, Dai J, et al. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytotropic differentiation driver Irf8 in acute promyelocytic leukemia cells. Cell Death Dis. 2017;8:e2782.

18. Lee JM, Kang JH, Song SY, Yoon SI, Ko HJ, et al. Mechanism underlying the suppressor activity of retinoic acid on IL-4-induced IgE synthesis and its physiological implication. Cell Immunol. 2017;322:49–55.

19. Weiss RH. Metabolomics and metabolic reprogramming in kidney disease. Semin Nephrol. 2018;38:175–82.

20. Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539:112–7.

21. Bai J, Yeh S, Qiu X, Hu L, Zeng J, Cai Y, et al. TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR-900-3p/vimentin signals. Oncogene. 2018;37:5901–12.

22. Wang M, Sun Y, Xu J, Liu J, Wang K, Yang DR, et al. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. Int J Cancer. 2018;143:100–12.

23. Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, et al. LncRNA-SARC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor (AR)/miR-143-3p signals. Cell Death Differ. 2017;24:1502–17.

24. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactomic analyses. Nucleic Acids Res. 2017;45:W98–102.

25. Jin R, Lin H, Li G, Xu J, Shi L, Chang C, et al. TR4 nuclear receptor suppresses RCC cell invasion via downregulating the EphA2 expression. Cell Death Dis. 2018;9:283.

26. Shen J, Lin H, Li G, Jin RA, Shi L, Chen M, et al. TR4 nuclear receptor enhances the cisplatin chemosensitivity via altering the ATF3 expression to better suppress HCC cell growth. Oncotarget. 2016;7:32088–99.

27. Kim E, Liu NC, Yu IC, Lin HY, Lee YF, Sparks JD, et al. Metformin inhibits nuclear receptor TR4-mediated hepatic stearyol-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes. 2011;60:1493–503.

28. Gnarra JR, Toni K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90.

29. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6:734–45.

30. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Sniper J, et al. Sunitib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010;70:1053–62.

31. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:3584–90.

32. Adelyaye-Ogala R, Damayanti NP, Orillon AR, Arisa S, Chintala S, Titus MA et al. Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma. Cancer Res. 2018;78:2886–96.

33. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. mr141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20:2617–30.

34. Lou N, Ruan AM, Qiu B, Bao L, Xu YC, Zhao Y, et al. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2017;35:e37–6 e14.

35. van der Mijn JC, Brixterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, et al. Sunitinib activates Axin signaling in renal cell cancer. Int J Cancer. 2016;138:3002–10.
36. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70:10090–10100.

37. Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 2014;74:253–62.

38. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007;26:3909–19.

39. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69:6871–8.

40. Tannir NM, Schwab G, Grunwald V. Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma. Curr Oncol Rep. 2017;19:14.

41. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–25.

42. Zhou XE, Suino-Powell KM, Xu Y, Chan CW, Tanabe O, Kruse SW, et al. The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor. J Biol Chem. 2011;286:2877–85.

43. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63:2590–9.

44. Liu Q, Tong D, Liu G, Xu J, Do K, Geary K, et al. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1/STAT3 axis-regulated EMT. Cell Death Dis. 2017;8:e3007.

45. Liu J, Li M, Song B, Jia C, Zhang L, Bai X, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 2013;31:264–70.

46. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242.

47. Chandel NS, Avizondis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 2016;23:569–70.

48. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beekers A, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16:839–47.

49. Chae YK, Aya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7:40767–80.

50. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2:57.

51. Shalita A, Weiss JS, Chalker DK, Ellis CN, Greenspan A, Katz HI, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34:482–5.